Evidence map›Paper›PMID 40187635›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2025

Refining early detection of Marburg Virus Disease (MVD) in Rwanda: Leveraging predictive symptom clusters to enhance case definitions.

Olivier Nsekuye, Frederick Ntabana, Hugues Valois Mucunguzi, Ziad El-Khatib, Eric Remera, Lyndah Makayotto, Menelas Nkeshimana, David Turatsinze, Frederic Ntirenganya, Semakula Muhammed and 8 more

Abstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Olivier NsekuyeRwanda Biomedical Centre, Kigali, Rwanda; Adventist University of Central Africa (AUCA), Kigali, Rwanda. Electronic address: nsekuye.olivier003@gmail.com.
Frederick NtabanaRwanda Biomedical Centre, Kigali, Rwanda.
Hugues Valois MucunguziRwanda Biomedical Centre, Kigali, Rwanda.
Ziad El-KhatibDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Eric RemeraRwanda Biomedical Centre, Kigali, Rwanda.
Lyndah MakayottoWorld Health Organization, Kigali, Rwanda.
Menelas NkeshimanaRwanda Ministry of Health, Kigali, Rwanda.
David TuratsinzeThe University Teaching Hospital of Kigali (CHUK), Kigali, Rwanda.
Frederic NtirenganyaRwanda Biomedical Centre, Kigali, Rwanda.
Semakula MuhammedRwanda Ministry of Health, Kigali, Rwanda.
Athanase RukundoRwanda Ministry of Health, Kigali, Rwanda.
Brian ChiromboWorld Health Organization, Kigali, Rwanda.
Richard MuvunyiRwanda Development Board (RDB), Kigali, Rwanda.
Claude Mambo MuvunyiRwanda Biomedical Centre, Kigali, Rwanda.
Pacifique NizeyimanaAdventist University of Central Africa (AUCA), Kigali, Rwanda.
Yvan ButeraRwanda Ministry of Health, Kigali, Rwanda.
Sabin NsanzimanaRwanda Ministry of Health, Kigali, Rwanda.
Edson RwagasoreRwanda Biomedical Centre, Kigali, Rwanda.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundMarburg Virus Disease (MVD) poses a significant global health risk due to its high case fatality rates (24%-88%) and the diagnostic challenges posed by its nonspecific early symptoms, which overlap with other febrile illnesses like malaria. This study analyzed symptom patterns from the 2024 MVD outbreak in Rwanda to refine case definitions and enhance early detection.

methodsA retrospective analysis was conducted of 6613 suspected MVD cases (66 positive, 6547 negative) reported between September 27 and December 20, 2024. Symptom prevalence and predictive value were assessed using multiple logistic regression models with L1 and L2 regularization to identify the most predictive symptoms. Models were validated using 5-fold cross-validation, with performance assessed through ROC analysis and standard accuracy metrics.

resultsFever (78.8%), fatigue (63.6%), and headache (57.6%) were identified as the most common early symptoms, while hemorrhagic signs were rare (3.0%). The model achieved high accuracy (99.04%) and an area under the receiver operating characteristic curve of 0.824, identifying fever, fatigue, nausea/vomiting, joint pain, and sore throat as key predictors.

conclusionEarly symptom clusters, especially constitutional and gastrointestinal signs outperformed hemorrhagic symptoms for MVD detection. Findings challenge current case definitions, emphasizing the need for revised public health messaging and healthcare worker training. Integrating symptom-based models into surveillance could enhance detection, especially in resource-limited settings.

Indexed as

Marburg Virus DiseaseAdolescentAdultDisease OutbreaksEarly DiagnosisFemaleFeverHumansMaleMarburgvirusMiddle AgedRetrospective StudiesROC CurveRwandaYoung AdultEarly detectionMachine learningMarburg Virus DiseaseOutbreak responseSymptom patterns

Identifiers

PMID40187635
PMCPMC12149021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.